Kera Capital Partners Inc. Sells 106 Shares of Cencora, Inc. $COR

Kera Capital Partners Inc. reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 9.9% in the 2nd quarter, Holdings Channel reports. The firm owned 964 shares of the company’s stock after selling 106 shares during the quarter. Kera Capital Partners Inc.’s holdings in Cencora were worth $289,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. AG2R LA Mondiale Gestion D Actifs bought a new position in Cencora during the 1st quarter worth $1,910,000. Swedbank AB raised its position in Cencora by 4.2% during the 1st quarter. Swedbank AB now owns 1,485,862 shares of the company’s stock worth $413,203,000 after purchasing an additional 60,087 shares during the last quarter. Voya Investment Management LLC raised its position in Cencora by 30.2% during the 1st quarter. Voya Investment Management LLC now owns 404,319 shares of the company’s stock worth $112,437,000 after purchasing an additional 93,673 shares during the last quarter. Modern Wealth Management LLC raised its position in Cencora by 16.7% during the 1st quarter. Modern Wealth Management LLC now owns 1,039 shares of the company’s stock worth $289,000 after purchasing an additional 149 shares during the last quarter. Finally, Strs Ohio bought a new position in Cencora during the 1st quarter worth $16,660,000. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on COR shares. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Jefferies Financial Group lifted their price objective on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Finally, Wells Fargo & Company lifted their price objective on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $311.25.

Cencora Stock Performance

COR stock opened at $302.83 on Friday. The stock has a 50-day moving average price of $293.24 and a 200-day moving average price of $285.74. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm has a market cap of $58.71 billion, a PE ratio of 31.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the company posted $3.34 EPS. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 22.63%.

Insider Activity

In other news, CEO Robert P. Mauch sold 4,968 shares of the firm’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the sale, the chief executive officer directly owned 42,351 shares in the company, valued at $12,455,852.61. This trade represents a 10.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the firm’s stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the sale, the chairman owned 309,913 shares of the company’s stock, valued at approximately $90,702,237.71. This represents a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,125 shares of company stock valued at $9,993,789. 10.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.